Biotech

All Articles

AC Immune finds 'landmark' potential in Alzheimer's medicine records

.After greater than two decades of work with neurodegenerative diseases, Swiss biotech a/c Immune ca...

GSK loses ph. 2 HPV injection over shortage of best-in-class potential

.GSK has ditched a phase 2 human papillomavirus (HPV) vaccination coming from its pipe after choosin...

OS Therapies refiles $6M IPO to fund HER2 medication, preclinical ADCs

.Operating system Therapies are going to note on the NYSE American inventory swap today via a $6.4 m...

ALX's fizzling CD47 action cost sends sell spiraling down

.ALX Oncology's phase 2 stomach cancer cells response cost has actually weakened. After seeing its C...

Ionis axes eye health condition coming from aim ats of Roche-partnered possibility after data disappoint

.An Additional of Ionis Pharmaceuticals' essential midphase readouts has actually disappointed assum...

Biogen's chief executive officer pointed out no high-risk deals in 2023. He's ready to become strong

.While Biogen's pharma peers are hunting for late-stage possessions with little risk, chief executiv...

Instil refills pipeline in $2B biobucks handle ImmunOnco

.Instil Biography has been a biotech trying to find a pipeline after it scrapped its own lead assets...

Biogen ignores Denali Alzheimer's collab

.Biogen has handed back civil liberties to an early Alzheimer's condition plan to Denali Therapeutic...

Takeda touches brand-new mind people oncology organization-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of notable management hirings, firings and also...

Vertex, hammered through AATD once more, goes down 2 assets on discard heap

.Vertex's effort to alleviate an uncommon hereditary illness has hit one more trouble. The biotech t...